Parkhurst MR - Search Results

1

A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers.

Hanada KI, Zhao C, Gil-Hoyos R, Gartner JJ, Chow-Parmer C, Lowery FJ, Krishna S, Prickett TD, Kivitz S, Parkhurst MR, Wong N, Rae Z, Kelly MC, Goff SL, Robbins PF, Rosenberg SA, Yang JC. Hanada KI, et al. Among authors: parkhurst mr. Cancer Cell. 2022 May 9;40(5):479-493.e6. doi: 10.1016/j.ccell.2022.03.012. Epub 2022 Apr 21. Cancer Cell. 2022. PMID: 35452604 Free PMC article.

2

Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen.

Wang RF, Parkhurst MR, Kawakami Y, Robbins PF, Rosenberg SA. Wang RF, et al. Among authors: parkhurst mr. J Exp Med. 1996 Mar 1;183(3):1131-40. doi: 10.1084/jem.183.3.1131. J Exp Med. 1996. PMID: 8642255 Free PMC article.

3

Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes.

Topalian SL, Gonzales MI, Parkhurst M, Li YF, Southwood S, Sette A, Rosenberg SA, Robbins PF. Topalian SL, et al. J Exp Med. 1996 May 1;183(5):1965-71. doi: 10.1084/jem.183.5.1965. J Exp Med. 1996. PMID: 8642306 Free PMC article.

4

Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.

Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA, Kawakami Y. Parkhurst MR, et al. J Immunol. 1996 Sep 15;157(6):2539-48. J Immunol. 1996. PMID: 8805655

5

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.

Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE. Rosenberg SA, et al. Among authors: parkhurst mr. Nat Med. 1998 Mar;4(3):321-7. doi: 10.1038/nm0398-321. Nat Med. 1998. PMID: 9500606 Free PMC article. Clinical Trial.

6

gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand.

Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP. Overwijk WW, et al. Among authors: parkhurst mr. J Exp Med. 1998 Jul 20;188(2):277-86. doi: 10.1084/jem.188.2.277. J Exp Med. 1998. PMID: 9670040 Free PMC article.

7

The use of melanosomal proteins in the immunotherapy of melanoma.

Kawakami Y, Robbins PF, Wang RF, Parkhurst M, Kang X, Rosenberg SA. Kawakami Y, et al. J Immunother. 1998 Jul;21(4):237-46. doi: 10.1097/00002371-199807000-00001. J Immunother. 1998. PMID: 9672845 Review.

8

Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2).

Parkhurst MR, Fitzgerald EB, Southwood S, Sette A, Rosenberg SA, Kawakami Y. Parkhurst MR, et al. Cancer Res. 1998 Nov 1;58(21):4895-901. Cancer Res. 1998. PMID: 9809996

9

Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.

Kawakami Y, Robbins PF, Wang X, Tupesis JP, Parkhurst MR, Kang X, Sakaguchi K, Appella E, Rosenberg SA. Kawakami Y, et al. Among authors: parkhurst mr. J Immunol. 1998 Dec 15;161(12):6985-92. J Immunol. 1998. PMID: 9862734

10

Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue.

Clay TM, Custer MC, McKee MD, Parkhurst M, Robbins PF, Kerstann K, Wunderlich J, Rosenberg SA, Nishimura MI. Clay TM, et al. J Immunol. 1999 Feb 1;162(3):1749-55. J Immunol. 1999. PMID: 9973438

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

62 results

Search Page